Literature DB >> 28039520

Natalizumab-associated progressive multifocal leukoencephalopathy: successful treatment without plasma exchange and its associated risks.

Eimer Maloney1, Anna Molloy2, Mariam Al Hussona2, Luke O'Donnell2, Ronan Killeen3, Christopher McGuigan2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 28039520     DOI： 10.1007/s00415-016-8372-0

Source DB:  PubMed          Journal:  J Neurol        ISSN： 0340-5354            Impact factor:   4.849


× No keyword cloud information.
  10 in total

1.  Immune reconstitution inflammatory syndrome in natalizumab-associated PML.

Authors:  I L Tan; J C McArthur; D B Clifford; E O Major; A Nath
Journal:  Neurology       Date:  2011-08-10       Impact factor: 9.910

2.  Minimal supportive treatment in natalizumab-related PML in a MS patient.

Authors:  Patrice H Lalive; Claire Bridel; Ruxandra Iancu Ferfoglia; Laurent Kaiser; Renaud Du Pasquier; Frederik Barkhof; Sven Haller
Journal:  J Neurol Neurosurg Psychiatry       Date:  2014-06-23       Impact factor: 10.154

3.  Treatment of progressive multifocal leukoencephalopathy-immune reconstitution inflammatory syndrome with intravenous immunoglobulin in a patient with multiple sclerosis treated with fingolimod after discontinuation of natalizumab.

Authors:  Z Calic; C Cappelen-Smith; S J Hodgkinson; A McDougall; R Cuganesan; B J Brew
Journal:  J Clin Neurosci       Date:  2014-12-15       Impact factor: 1.961

4.  Immune-reconstitution Inflammatory Syndrome in Multiple Sclerosis Patients Treated With Natalizumab: A Series of 4 Cases.

Authors:  Rosy N'gbo N'gbo Ikazabo; Christian Mostosi; Bénédicte Quivron; Xavier Delberghe; Kaoutar El Hafsi; Andreas P Lysandropoulos
Journal:  Clin Ther       Date:  2016-02-05       Impact factor: 3.393

Review 5.  Update on PML and PML-IRIS occurring in multiple sclerosis patients treated with natalizumab.

Authors:  B K Kleinschmidt-DeMasters; Augusto Miravalle; Jeffrey Schowinsky; John Corboy; Timothy Vollmer
Journal:  J Neuropathol Exp Neurol       Date:  2012-07       Impact factor: 3.685

Review 6.  Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring.

Authors:  Ludwig Kappos; David Bates; Gilles Edan; Mefkûre Eraksoy; Antonio Garcia-Merino; Nikolaos Grigoriadis; Hans-Peter Hartung; Eva Havrdová; Jan Hillert; Reinhard Hohlfeld; Marcelo Kremenchutzky; Olivier Lyon-Caen; Ariel Miller; Carlo Pozzilli; Mads Ravnborg; Takahiko Saida; Christian Sindic; Karl Vass; David B Clifford; Stephen Hauser; Eugene O Major; Paul W O'Connor; Howard L Weiner; Michel Clanet; Ralf Gold; Hans H Hirsch; Ernst-Wilhelm Radü; Per Soelberg Sørensen; John King
Journal:  Lancet Neurol       Date:  2011-08       Impact factor: 44.182

7.  MRI characteristics of early PML-IRIS after natalizumab treatment in patients with MS.

Authors:  Mike P Wattjes; Martijn T Wijburg; Anke Vennegoor; Birgit I Witte; Marlieke de Vos; Nancy D Richert; Bernard M J Uitdehaag; Frederik Barkhof; Joep Killestein
Journal:  J Neurol Neurosurg Psychiatry       Date:  2015-09-14       Impact factor: 10.154

Review 8.  Progressive multifocal leukoencephalopathy: current treatment options and future perspectives.

Authors:  Dejan Pavlovic; Andriani C Patera; Fredrik Nyberg; Marianne Gerber; Maggie Liu
Journal:  Ther Adv Neurol Disord       Date:  2015-11       Impact factor: 6.570

9.  Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy.

Authors:  Tatiana Plavina; Meena Subramanyam; Gary Bloomgren; Sandra Richman; Amy Pace; Sophia Lee; Brian Schlain; Denise Campagnolo; Shibeshih Belachew; Barry Ticho
Journal:  Ann Neurol       Date:  2014-10-24       Impact factor: 10.422

Review 10.  Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group.

Authors:  C McGuigan; M Craner; J Guadagno; R Kapoor; G Mazibrada; P Molyneux; R Nicholas; J Palace; O R Pearson; D Rog; C A Young
Journal:  J Neurol Neurosurg Psychiatry       Date:  2015-10-22       Impact factor: 10.154
  10 in total
  1 in total

Review 1.  The use of natalizumab for multiple sclerosis.

Authors:  Rachel Brandstadter; Ilana Katz Sand
Journal:  Neuropsychiatr Dis Treat       Date:  2017-06-28       Impact factor: 2.570
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.